A personalized approach to halting kidney disease

inRegen’s personalized progenitor cell therapy injects autologous kidney cells (REACT) into patients’ damaged kidneys, where cells migrate and restore kidney function. The cell-based treatment is showing signs of promise in ongoing phase 2 trials.

Like Comment
Page of
Go to the profile of InRegen


CEO, InRegen

n over 50 years there was little development in the treatment of chronic kidney disease. At inRegen we are pioneers in the field of Chronic kidney treatment.

No comments yet.